Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Subscribe To Our Newsletter & Stay Updated